Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Critical Reviews in Oncology/Hematology|November 13, 2025
Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysisShunsuke Nakatani, Takuya Hayashi, Aoi Hosaka, et al.
Cancer Reports (Hoboken, N.J.)|January 17, 2021
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancerHideki Maeda, Kentaro Takeda, Hisashi Urushihara, et al.
Cancer Treatment Reviews|March 20, 2025
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysisShunsuke Nakatani, Takuya Hayashi, Keiko Yamamoto, et al.
International Journal of Clinical Pharmacy|November 3, 2022
Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999-2019Minami Nakao, Yuri Nakamura, Masafumi Shimokawa, et al.
Therapeutic Innovation & Regulatory Science|June 3, 2025
Characterization of Japanese Risk Management Plans after 10 Years of Implementation: 2013-2023Sono Sawada, Keiko Asao, Ryohei Kobayashi, et al.
Scientific Reports|May 26, 2021
Generation of somatic mitochondrial DNA-replaced cells for mitochondrial dysfunction treatmentHideki Maeda, Daisuke Kami, Ryotaro Maeda, et al.
Clinical Pharmacology and Therapeutics|May 15, 2022
Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021Hideki Maeda, Marika Uchida, Mikiko Kusano, et al.
Biological & Pharmaceutical Bulletin|April 4, 2022
Lag Time for New Innovative, First-in-Class, Drug Approval in JapanTakayuki Miyazaki, Michiyuki Komiyama, Naoki Matsumaru, et al.
Scientific Reports|July 4, 2020
High throughput single cell analysis of mitochondrial heteroplasmy in mitochondrial diseasesRyotaro Maeda, Daisuke Kami, Hideki Maeda, et al.
BMC Health Services Research|December 13, 2021
Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in JapanHideki Maeda, Ayano Okabe, Kenichi Sakakura, et al.
Pageof 8